These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 16627306

  • 1. Retention and attendance with supervised buprenorphine treatment: a case-note review.
    Bell J, Burrell T.
    Drug Alcohol Rev; 2006 Mar; 25(2):161-5. PubMed ID: 16627306
    [Abstract] [Full Text] [Related]

  • 2. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review.
    Bell J, Mutch C.
    Drug Alcohol Rev; 2006 Mar; 25(2):167-71. PubMed ID: 16627307
    [Abstract] [Full Text] [Related]

  • 3. Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002.
    Bell J, Burrell T, Indig D, Gilmour S.
    Drug Alcohol Depend; 2006 Jan 04; 81(1):55-61. PubMed ID: 15993552
    [Abstract] [Full Text] [Related]

  • 4. Short-term buprenorphine maintenance: treatment outcome.
    Galanter M, Dermatis H, Resnick R, Maslansky R, Neumann E.
    J Addict Dis; 2003 Jan 04; 22(3):39-49. PubMed ID: 14621343
    [Abstract] [Full Text] [Related]

  • 5. Heroin detoxification with a single high dose of buprenorphine.
    Kutz I, Reznik V.
    Isr J Psychiatry Relat Sci; 2002 Jan 04; 39(2):113-9. PubMed ID: 12227226
    [Abstract] [Full Text] [Related]

  • 6. Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling.
    Kornør H, Waal H, Ali RL.
    Drug Alcohol Rev; 2006 Mar 04; 25(2):123-30. PubMed ID: 16627301
    [Abstract] [Full Text] [Related]

  • 7. Optimising the benefits of unobserved dose administration for stable opioid maintenance patients: follow-up of a randomised trial.
    Bell JR, Ryan A, Mutch C, Batey R, Rea F.
    Drug Alcohol Depend; 2008 Jul 01; 96(1-2):183-6. PubMed ID: 18423901
    [Abstract] [Full Text] [Related]

  • 8. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence.
    Bell J, Shanahan M, Mutch C, Rea F, Ryan A, Batey R, Dunlop A, Winstock A.
    Addiction; 2007 Dec 01; 102(12):1899-907. PubMed ID: 17784896
    [Abstract] [Full Text] [Related]

  • 9. Network therapy: decreased secondary opioid use during buprenorphine maintenance.
    Galanter M, Dermatis H, Glickman L, Maslansky R, Sellers MB, Neumann E, Rahman-Dujarric C.
    J Subst Abuse Treat; 2004 Jun 01; 26(4):313-8. PubMed ID: 15182896
    [Abstract] [Full Text] [Related]

  • 10. Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation.
    Collins ED, Horton T, Reinke K, Amass L, Nunes EV.
    J Subst Abuse Treat; 2007 Mar 01; 32(2):167-75. PubMed ID: 17306725
    [Abstract] [Full Text] [Related]

  • 11. Quality of life among heroin users on buprenorphine versus methadone maintenance.
    Ponizovsky AM, Grinshpoon A.
    Am J Drug Alcohol Abuse; 2007 Mar 01; 33(5):631-42. PubMed ID: 17891656
    [Abstract] [Full Text] [Related]

  • 12. Subjective effects of additional doses of buprenorphine in patients on buprenorphine maintenance.
    Singhal A, Tripathi BM, Pal HR, Jena R, Jain R.
    Addict Behav; 2007 Feb 01; 32(2):320-31. PubMed ID: 16814937
    [Abstract] [Full Text] [Related]

  • 13. Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose.
    Clark NC, Lintzeris N, Muhleisen PJ.
    Med J Aust; 2002 Feb 18; 176(4):166-7. PubMed ID: 11913917
    [Abstract] [Full Text] [Related]

  • 14. Buprenorphine for acute heroin detoxification: diffusion of research into practice.
    Kovas AE, McFarland BH, McCarty DJ, Boverman JF, Thayer JA.
    J Subst Abuse Treat; 2007 Mar 18; 32(2):199-206. PubMed ID: 17306728
    [Abstract] [Full Text] [Related]

  • 15. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence.
    White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, Beebe KL.
    Drug Alcohol Depend; 2009 Jul 01; 103(1-2):37-43. PubMed ID: 19403243
    [Abstract] [Full Text] [Related]

  • 16. Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence.
    Kakko J, von Wachenfeldt J, Svanborg KD, Lidström J, Barr CS, Heilig M.
    Biol Psychiatry; 2008 Jan 15; 63(2):172-7. PubMed ID: 17850768
    [Abstract] [Full Text] [Related]

  • 17. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec 15; 16(92):232-5. PubMed ID: 18087797
    [Abstract] [Full Text] [Related]

  • 18. The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.
    Winstock AR, Lea T, Ritter A.
    Drug Alcohol Rev; 2007 Jul 15; 26(4):411-6. PubMed ID: 17564877
    [Abstract] [Full Text] [Related]

  • 19. Slow tapering from methadone maintenance in a program encouraging indefinite maintenance.
    Calsyn DA, Malcy JA, Saxon AJ.
    J Subst Abuse Treat; 2006 Mar 15; 30(2):159-63. PubMed ID: 16490679
    [Abstract] [Full Text] [Related]

  • 20. High dose buprenorphine in pregnancy.
    Ross D.
    Aust N Z J Obstet Gynaecol; 2004 Feb 15; 44(1):80. PubMed ID: 15089877
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.